HOME CAREERS CONTACT US KOREAN ENGLISH

SCIENCE

  1. HOME
  2. SCIENCE

NT-I7 is a Unique T Cell Amplifier

Interleukin-7 (IL-7) is Central to T Lymphocyte Development and Survival
IL-7 plays a key role in T cell development and survival1,2. When T cell numbers are low, the physiological level of IL-7 increases to stimulate T cell expansion. However, as a homeostatic cytokine, IL-7 levels do not rise dramatically in these settings, and recovery of T cell numbers is often a slow process3.

IL-7 acts through IL-7 receptor (IL-7R), which is expressed on naïve and memory CD4+ and CD8+ T cells. Thus, IL-7 promotes proliferation, maintenance, and functionality of these key T cell subsets mediating immune responses. On the other hand, IL-7R is expressed on regulatory T cells at low levels, which is a T cell subset involved in limiting T cell responses4.

At NeoImmuneTech, we are exploring the utility of IL-7 based therapeutics in enhancing immune function.
NT-I7 is a More Potent, Stable, and Long-Acting Human IL-7
NT-I7 (efineptakin alfa) is a human IL-7 fusion protein that overcomes the key limitations of endogenous IL-7. The IL-7 domain promotes T cell development which plays a central role in immune response. The N-terminus of the IL-7 domain was engineered to overcome its structural instability and to enable mass production of NT-I7. The hyFc® domain extends the half-life of IL-7, thereby enhancing bioavailability which provides better potency and stability.
IL-7 Domain HyFc® Domain
NT-I7 Boosts T Cell Numbers and Functionality to Enhance Immune Function and Potentially Provide Greater Therapeutic Benefits to Patients
At NeoImmuneTech, we focus on developing NT-I7 in Immuno-oncology and infectious disease See How NT-I7 Could
Help in Cancer Treatment See How NT-I7 Could
Enhance Immunity to Infectious
Diseases See How NT-I7 Could
Improve Immunological
Disorders See Our Scientific Publications
References

1. Mazzucchelli, Renata, and Scott K. Durum. "Interleukin-7 receptor expression: intelligent design." Nature Reviews Immunology 7.2 (2007): 144-154.
2. Fry, Terry J., and Crystal L. Mackall. "Interleukin-7: from bench to clinic." Blood, The Journal of the American Society of Hematology 99.11 (2002): 3892-3904.
3. Ponchel, Frederique, et al. "Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia." Arthritis Res Ther 7.1 (2004): R80.
4. Seddiki, N. Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. "Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells." J Exp Med 203 (2006): 1693-1700.

Homeostatic Proliferation

In cancer patients, NT-I7 increases the absolute lymphocyte count (ALC). In patients with pancreatic cancer, the ALC significantly increased 3-fold over baseline by week 3 and remained elevated for the duration of follow up. In patients with glioblastoma, the ALC was significantly increased even when patients were treated with chemotherapy, which is known to weaken the immune system.
Absolute lymphocyte counts (ALC)

Lymphocytes (ALC) significantly increased (3x over baseline) by week 3 and remained elevated for the duration of the follow-up. Analysis based on 17 evaluable patients.

Lymphocytes (ALC) increased and remain elevated even when patients were receiving chemotherapy (temozolomide, TMZ).

Lymphocytes (ALC) significantly increased (3x over baseline) by week 3 and remained elevated for the duration of the follow-up. Analysis based on 17 evaluable patients.

Lymphocytes (ALC) increased and remain elevated even when patients were receiving chemotherapy (temozolomide, TMZ).

Among all lymphocyte types, T cells, the white blood cells that protect you from threats like cancer and infectious diseases, are increased the most. All T cell subsets increase with NT-I7, including the naïve (Tnaive), stem-cell memory (Tscm), central memory (Tcm) and effector memory (Tem & Temra). Less differentiated subsets, with better anti-cancer abilities, are increased the most.
CD4+ and CD8+ T cells
CD8+ T cells subsets

CD4+ and CD8+ T cells, following the same pattern, increased 4x over baseline by week 3 and remained increased until week 9 (last measurement). Analysis based on 17 evaluable patients.
(*p≤0.05; **p≤0.001; ***p≤0.0001; ***p≤0.00001)

Dynamics of the CD8+ T cell subsets after NT-I7 administration. The associated upregulation of Ki67 (data not shown), a marker of cell proliferation, suggests that proliferation, rather than re-distribution, is driving the increase of T cells.

CD4+ and CD8+ T cells, following the same pattern, increased 4x over baseline by week 3 and remained increased until week 9 (last measurement). Analysis based on 17 evaluable patients.
(*p≤0.05; **p≤0.001; ***p≤0.0001; ***p≤0.00001)

CD8+ T cells subsets

Dynamics of the CD8+ T cell subsets after NT-I7 administration. The associated upregulation of Ki67 (data not shown), a marker of cell proliferation, suggests that proliferation, rather than re-distribution, is driving the increase of T cells.

Source

Naing A, Kim R, Barve M. “Preliminary biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer” (2021) J Immunoth Cancer 9(Suppl 2):A1-A1054

Zhou A, Rettig M, Foltz Jennifer. “NT-I7,a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C.

CLOSE

Increased Tumor Infiltrating Lymphocytes (TIL)

After NT-I7 treatment we observe an increase of potent chemoattractants that mediate the migration of lymphocytes into the tumor. CCL19, a chemokine involved in the formation of tertiary lymphoid structures (TLS) known to correlate with better prognosis, is also significantly increased in patients after NT-I7 treatment.
Plasmatic chemokines
Tumor infiltrating lymphocytes (TIL)

Potent chemoattractants and mediators of TLS formation significantly increased after the first NT-I7+pembro dose. These chemokines recruit lymphocytes into the tumor and facilitate T cell anti-tumor activity. Analysis based on 17 evaluable patients. (*p≤0.05; **p≤0.001; ***p≤0.0001; ***p≤0.00001)

Pre-Tx = Pre-treatment & On-Tx = On-treatment.

Representative pre- and on-treatment paired biopsies for a subject with clear cell ovarian cancer. Immunohistochemical staining showed a significant increase of CD8+ T cells (brown) in the on-treatment sample.

Plasmatic chemokines

Potent chemoattractants and mediators of TLS formation significantly increased after the first NT-I7+pembro dose. These chemokines recruit lymphocytes into the tumor and facilitate T cell anti-tumor activity. Analysis based on 17 evaluable patients. (*p≤0.05; **p≤0.001; ***p≤0.0001; ***p≤0.00001)

Tumor infiltrating lymphocytes (TIL)

Pre-Tx = Pre-treatment & On-Tx = On-treatment.

Representative pre- and on-treatment paired biopsies for a subject with clear cell ovarian cancer. Immunohistochemical staining showed a significant increase of CD8+ T cells (brown) in the on-treatment sample.

Source

Kim R, Barve M, Mamdani H, “Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C.

NeoImmuneTech, Phase 1, FIH study

Tumor-infiltrating lymphocytes (TILs) are not only a powerful prognostic marker but also a potential key breakthrough for anti-tumor therapy. NT-I7 consistently boosts CD8+ T cell infiltration, even in immunologically cold, hard-to-treat indications like MSS-CRC and Pancreatic cancer.
TILs by Immunofluorescence
TILs and efficacy
TILs by Immunofluorescence

Pooled data of pre-treatment and on-treatment paired biopsies showed a significant increase of CD8+ T cell infiltration. *p<0.05; ***p<0.0001

TILs and efficacy

Pooled data of pre-treatment and on-treatment paired biopsies showed a significant increase of CD8+ T cell infiltration. *p<0.05; ***p<0.0001

Subjects with a higher increase in TILs (y axis) experienced greater tumor reduction (x axis) with treatment.

Subjects with a higher increase in TILs (x axis) had higher overall survival (OS) (y axis).
Wks = weeks

Source

Naing A, Ferrando-Martinez S, Wolfarth A, "NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells and provides a more immunogenic tumor microenvironment: Biomarker data from the NIT-110 study" Poster Presented at ESMO; Sep. 1st, 2022; Paris, France.

Naing A, Ferrando-Martinez S, Ware M, "NT-I7, a long-acting IL-7, plus pembrolizumab favors CD8 T-cell infiltration in liver metastases of heavily pre-treated, immunologically cold, MSS-colorectal and pancreatic cancer" Oral Presentation Presented at SITC; Nov 11, 2022; Boston, MA.

CLOSE

Increased T-Cell Receptor (TCR) Clonality in TIL

Subjects showed an increase in intratumoral clonality on-treatment, suggesting there is a selective expansion of certain clonotypes, potentially tumor-specific, in patients with favorable clinical outcomes.
Lymphocytes infiltrating the tumor had increased clonality, especially in patients with disease control. In most patients, the size of the top 10 on-treatment clonotypes were twice as large on-treatment compared to pre-treatment. Increased clonality of the 2 subjects with partial response is shown in this figure. Each color segment represents an individual TCR clonotype.

Source

Naing A, Ferrando-Martinez S, Wolfarth A, "NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells and provides a more immunogenic tumor microenvironment: Biomarker data from the NIT-110 study" Poster Presented at ESMO; Sep. 1st, 2022; Paris, France.

CLOSE

Induction of Stemness

Stem-cell Memory CD8+ T cells (Tscm), the CD8+ T cell subset with self-renewal capabilities that have shown better antitumor activity compared with other memory T cell subsets, significantly increase after NT-I7 treatment. Remarkably, while all T cell subsets increase by ~5-fold with treatment, NT-I7 preferentially expands the Tscm subset, with increases up to 50-fold compared to baseline levels.
Stem-cell memory CD8+ T cells (Tscm)
CD8+ Tscm absolute numbers peaked at week 3 with a 50-fold increase over baseline, while the other CD8+ T cell subset increased an average of ~5-fold. After a second dose of NT-I7 in week 6, CD8+ Tscm levels increased again. (*p≤0.05; **p ≤ 0.001; ***p ≤0.0001; ****p ≤0.00001)

Source

Naing A, Kim R, Barve M. “Preliminary biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C.

CLOSE

Scientific Publications

NT-I7 Posters and Presentations – Clinical studies and translational research
  1. Naing A, Mamdani H, Barve M, "NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors." Poster Presented At SITC; November 1-5, 2023; San Diego, CA (Click Here )
  2. Lisco A, Ye P, Anderson M, "Cytokine-based immunotherapy with long-acting human recombinant IL-7 in HPV-related diseases associated with idiopathic CD4 lymphopenia." Poster Presented At ICIS; October 15-18, 2023; Athens, Greece
  3. Perez-Diez A, Liu X, Bennett A, "A long-acting form of recombinant human IL-7 shows biologic effect in both a pre-clinical model and a clinical pilot study of Idiopathic CD4 Lymphopenia." Poster Presented At ICIS; October 15-18, 2023; Athens, Greece
  4. Webb M, Burns T, Twohy E, "Efficacy and Safety Study of Neoadjuvant Efineptakin alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma." Poster Presented At ASCO; June 2-6, 2023; Chicago, IL (Click Here )
  5. Ghobadi A, Budde L., Galal A, "A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma." Poster Presented At ASH; Dec 10-13, 2022; New Orleans, LA (Click Here )
  6. Naing A, Ferrando-Martinez S, Ware M, "NT-I7, a long-acting IL-7, plus pembrolizumab favors CD8 T-cell infiltration in liver metastases of heavily pre-treated, immunologically cold, MSS-colorectal and pancreatic cancer" Oral Presentation Presented at SITC; Nov 11, 2022; Boston, MA. (Click Here )
  7. Butt O, Tao Y, Huang J, "A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy" Poster Presented at SITC; Nov 11, 2022; Boston, MA. (Click Here )
  8. Kang H, Spitzer M, Kim MO, "NT-I7 for the treatment of locally recurrent squamous cell carcinoma of head and neck undergoing salvage surgery: a clinical trial in progress" Poster Presented at SITC; Nov 10, 2022; Boston, MA (Click Here )
  9. Naing A, Ferrando-Martinez S, Wolfarth A, "NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells and provides a more immunogenic tumor microenvironment: Biomarker data from the NIT-110 study" Poster Presented at ESMO; Sep. 1st, 2022; Paris, France. (Click Here )
  10. Kim R, Mamdani H, Brave M, "Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-Naïve Advanced MSS-Colorectal Cancer" Poster Presented at ESMO-GI; Jul. 1st, 2022; Barcelona, Spain. (Click Here )
  11. Naing A, Mamdani H, Brave M, "Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-Naïve Advanced Pancreatic Cancer" Poster Presented at ESMO-GI; Jun. 30th, 2022; Barcelona, Spain. (Click Here )
  12. Gastman B, Fling S, Ansstas G, "A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report." Poster Presented at ASCO; Jun. 6th, 2022; Chicago, IL. (Click Here )
  13. Naing A, Mamdani H, Brave M, "Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study." Poster Presented at ASCO; Jun. 5th, 2022; Chicago, IL. (Click Here ) **Selected for poster discussion session
  14. Ghobadi A, Budde L, Galal A, "Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma" Poster Presented at ASCO; Jun. 4th, 2022; Chicago, IL. (Click Here )
  15. Sohn J, Kim G, Lee K, “Phase 1b/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.” Poster Presented at ASCO; Jun. 1st, 2022; Chicago, IL.* (Click Here )
  16. Campian Jian Li, et al. “A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy” Oral Presentation Presented at SNO; Nov 19th, 2021; Boston, MA. (Click Here )
  17. Zhou A, Rettig M, Foltz Jennifer. “NT-I7,a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C. (Click Here )
  18. Naing A, Kim R, Barve M. “Preliminary biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C. (Click Here )
  19. Kim R, Barve M, Mamdani H, “Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C. (Click Here )
  20. Campian Jian Li, et al. “A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data.” Poster Presented at ASCO; May. 28th, 2021; Virtual Presentation. (Click Here )
  21. Naing A, Fan J, Lee B, “Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: The phase 1b data report.” Poster Presented at ASCO; May. 28th, 2021; Virtual Presentation. (Click Here )
  22. Sohn J, Im Y, “Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study.” Poster Presented at SITC; Oct. 10th, 2020; Virtual Presentation.* (Click Here )
  23. Sohn J, Park K, Ahn H, “Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).” Poster Presented at ASCO; May. 25th, 2020; Virtual Presentation.* (Click Here )
  24. Lee S, Choi D, Heo M, “Hyleukin-7, a long-acting interleukin-7, increased absolute lymphocyte counts after subcutaneous and intramuscular administration in healthy subjects.” Poster Presented at AACR; Mar. 30th, 2019; Atlanta, GA.* (Click Here )
  25. Heo M, Sohn J, Lee M, “Phase 1b study of GX-I7, a long-acting interleukin-7, evaluating the safety, pharmacokinetics and pharmacodynamics profiles in patients with advanced solid cancers.” Poster Presented at SITC; Nov. 6th, 2019; National Harbor, MD.* (Click Here )
NT-I7 Posters and Presentations – Nonclinical research
  1. Lee SM, Kim M, Ferrando-Martinez S, "rhIL-7-hyFc (efineptakin-alfa, NT-I7) increases tumor-specific CD8+ T cells despite FOLFOX cytotoxicity effect." Poster Presented At AACR; April 5-10, 2024; San Diego, CA (Click Here )
  2. Xiang J, Devenport J, Carter A, "An “off-the-shelf” CD2 Universal CAR-T therapy combined with a long-acting IL-7 for T-cell malignancies ." Oral Presented At ASH; December 9-12, 2023; San Diego, CA (Click Here )
  3. Lee M, Ferrando-Martinez S, Im SK, "NT-I7 and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that favors anti-tumor efficacy in combination with checkpoint inhibitors." Poster Presented At SITC; November 1-5, 2023; San Diego, CA (Click Here )
  4. Li Y, Hu T, Kesarwani A, "Long-acting recombinant interleukin-7, rhIL-7-hyFc, improves survival following oncolytic Zika virus treatment in the SB28 immunosuppressive and treatment-resistant murine glioma model." Poster Presented At SNO; November 16-19, 2023; Vancouver, Canada (Click Here )
  5. Niavi C, Lee J, Valanparambil R, "Effect of NT-I7 treatment on CD4 T cells during chronic LCMV ." Poster Presented At ICIS; October 15-18, 2023; Athens, Greece
  6. Lee J, Niavi C, Ahn E, "NT-I7, a long-acting interleukin-7, promotes expansion and mobilization of virus-specific PD-1+Tcf-1+ stem-like CD8 T cells during chronic viral infection." Poster Presented At ICIS; October 15-18, 2023; Athens, Greece
  7. Lee M, Im SK, Baek S, "The combination of NT-I7 and hIL-2/TCB2c promotes the development of an immune-stimulatory tumor microenvironment that enhances the anti-tumor efficacy in combination with checkpoint inhibitors ." Poster Presented At KAI; September 13-16, 2023; Incheon, Korea
  8. Chen M, Chen I, Supabphol S, "NT-I7 as an adjuvant to DNA neoantigen vaccination enhances and prolongs neoantigen-specific anti-tumor immunity." Poster Presented At AACR; April 14-19, 2023; Orlando, FL (Click Here )
  9. Phoon Y, Kai K, Wolfarth A, "NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model" Poster Presented at SITC; Nov 10, 2022; Boston, MA. (Click Here )
  10. Lee KJ, Tae N, Kang YW, "Redirecting IL-7-induced bystander tumor-infiltrating lymphocytes by bispecific T cell engager augments antitumor response" Poster Presented at SITC; Nov 10, 2022; Boston, MA. (Click Here )
  11. Zou Y, Jiao Y, Wolfarth A, "NT-I7, a long-acting recombinant human interleukin-7, enhances T cell reconstitution following total body irradiation" Poster Presented at RRS; Oct 17, 2022; Waikoloa Village, HI. (Click Here )
  12. Zou Y, Jiao Y, Wolfarth A, "NT-I7, a long-acting recombinant human interleukin-7, enhances T cell reconstitution following total body irradiation" Oral Presentation Presented at RITN; Aug 4, 2022; Alexandria, VA. (Click Here )
  13. Baek S, Im SK, Lee M, "rhIL-7-hyFc (efineptakin alpha; NT-I7) enhances the anti-tumor response when combined with anti-TIGIT or anti-VEGF" Poster Presented at AACR; Apr. 13th, 2022; New Orleans, LA. (Click Here )
  14. Baek S, Im SK, Lee M, "rhIL-7-hyFc (efineptakin alpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex" Poster Presented at AACR; Apr. 13th, 2022; New Orleans, LA. (Click Here )
  15. Bardahl J, Jiao Y, Wolfarth A, “Effects of a novel long-acting IL-7 on T cell reconstitution following allogeneic hematopoietic cell transplantation” Poster Presented at Duke Pediatrics Research Retreat; Apr. 28th, 2022; Durham, NC. (Click Here )
  16. Niavi C, Lee J, McManus D, “Effect of NT-I7 treatment on CD8 T cell differentiation during chronic LCMV” Poster Presented at SIS 2022; Jun. 11th, 2022; Durham, NC. (Click Here )
  17. Liang T, Li, D, Ferrando-Martinez S, “Influence of NT-I7, an engineered long-acting interleukin-7, on CAR T cell therapy in liver cancer” Poster Presented at PEGS 2022; May 4th, 2022, Boston, MA. (Click Here )
  18. Campian, Jian Li, et al. ”A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8 cells and enhances survival in mouse glioma models.” Oral Presentation Presented at SNO 2020; Virtual Presentation. (Click Here )
  19. Park S, Kim J, Kang Y, “Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice” Poster Presented at SITC; Nov. 09th 2020; Virtual Presentation. (Click Here )
  20. Ghosh S, Yan R, Thotala S, “A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models” Poster Presented at SITC; Dec. 10th 2020; Virtual Presentation. (Click Here )
  21. O'Neal, Julie, et al. "In vivo efficacy of BCMA-iNKT-CAR is enhanced by NT-I7, a long-acting IL-7.” Oral Presentation Presented at 17th International Myeloma Workshop; Sep. 13th, 2019; Boston, MA. (Click Here )
  22. Campian, Jian Li, et al. "Effect of a novel long-acting interleukin-7 agonist, NT-I7, on survival in mouse models of glioma.” Abstract submitted for ASCO; May. 31st, 2019: e13516. (Click Here )
  23. Kim J, Hong S, Kim Y, "Hyleukin-7, the Fc-fused interleukin-7, generates anti-tumor activity by modulating both adaptive and innate immune cells in the tumor microenvironment.” Poster Presented at AACR; Mar. 30th, 2019; Atlanta, GA. * (Click Here )
  24. Cooper ML, Staser KW, Niswonge J, "A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates CART Proliferation, Differentiation, and Tumor Killing.” Poster Presented at TCT-Transplant & Cellular Therapy: Feb. 20th, 2019; Houston, TX. (Click Here )
  25. Staser KW, Cooper ML, Choi J, "Modeling Sezary Syndrome For Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy.” Poster Presented at TCT-Transplant & Cellule Therapy: Feb. 20th, 2019; Houston, TX. (Click Here )
  26. Staser KW, Cooper ML, Choi J, "Modeling Sezary Syndrome For Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy.” Poster Presented at ASH Annual Meeting; Dec. 2nd, 2018; San Diego, CA. (Click Here )
  27. Cooper M, Staser K, Davenport J, "A long-acting pharmacological grade interleukin-7 molecule logarithmically accelerates UCAR-T proliferation, differentiation, and tumor killing.” Oral Presentation Presented at ASH Annual Meeting; Dec. 2nd, 2018; San Diego, CA. (Click Here )
  28. Kim J, Choi D, Ji M, "Preclinical evaluation of the anti-tumor activity of Fc-fused interleukin-7 in both monotherapy and combination therapy.” Poster Presented at AACR; Apr. 14th, 2018; Chicago, IL. (Click Here )
Scientific Publications
  1. Kim, Anhye, et al. "Understanding the pharmacokinetic journey of fc-fusion protein, rhIL-7-hyFc, using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA." Antibody Therapeutics (2024). https://doi.org/10.1093/abt/tbae004
  2. Kwon, Dong-Il, et al. "Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells." Cell Report Medicine (2024). https://doi.org/10.1016/j.xcrm.2023.101362
  3. Lee, Minji, et al. "rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves anti-tumor efficacy of checkpoint inhibitors." Journal for ImmunoTherapy of Cancer (2024). https://doi.org/10.1136/jitc-2023-008001
  4. Xiang, Jingyu, et al. "An “off-the-shelf” CD2 Universal CAR-T therapy for T-cell malignancies." Leukemia (2023). https://doi.org/10.1038/s41375-023-02039-z
  5. O'Neal, Julie, et al. "Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7hyFc." Blood Advances (2023). https://doi.org/10.1182/bloodadvances.2023010032
  6. Ware, Michael B. et al. "The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal Cancers" Journal of Immunotherapy and Precision modalPageOne 5.4 (2022): 105-117.    https://doi.org/10.36401/JIPO-22-10
  7. Kim, Sojeong et al. "A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained functions and TCR diversity" Blood Advances (2022).    https://doi.org/10.1182/bloodadvances.2021006591
  8. Kim, Miriam Y. et al. "A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity" Nature Communications (2022).    https://doi.org/10.1038/s41467-022-30860-0
  9. Wolfarth, Alexandra A. et al. “Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy” Immune Network (2022).   https://doi.org/10.4110/in.2022.22.e5
  10. Campian, Jian L. et al. “Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 + T cells and enhances survival in mouse glioma models” Clinical Cancer Research (2022).   https://doi.org/10.1158/1078-0432.CCR-21-0947
  11. Kim, Miriam Y, et al. “CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy” JCI Insight (2021).   https://doi.org/10.1172/jci.insight.149819
  12. Kim, Ji-Hae, et al. “Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7.” BMB Reports (2021).   https://doi.org/10.5483/BMBRep.2021.54.1.257
  13. Foluso O Ademuyiwa, et al. “Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.” Breast Cancer Research and Treatment (2021).   https://doi.org/10.1007/s10549-021-06307-3
  14. Kim, Sora, et al. “Fc-fused IL-7 mobilizes long-term HSCs in a pro-B cell-dependent manner and synergizes with G-CSF and AMD3100.” Leukemia(2021).   https://doi.org/10.1038/s41375-021-01274-6
  15. Kim, Ji-Hae, et al. “Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.” Clinical and Translational Immunology (2020).   https://doi.org/10.1002/cti2.1168
  16. Lee, Sang Won, et al. "hIL-7-hyFc, a long-acting IL-7, increased absolute lymphocyte count in healthy subjects.” Clinical and Translational Science (2020). [Epub ahead of print]   https://doi.org/10.1111/cts.12800
  17. Choi, Young Woo, et al. "Intravaginal administration of Fc-fused IL7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells." Clinical Cancer Research 22.23 (2016): 5898-5908.   https://doi.org/10.1158/1078-0432.CCR-16-0423
  18. Lim, Jun Yeul, et al. "Biophysical stability of hyFc fusion protein with regards to buffers and various excipients." International journal of biological macromolecules 86 (2016): 622-629.   https://doi.org/10.1016/j.ijbiomac.2016.02.006
  19. Kang, Moon Cheol, et al. "Intranasal introduction of Fc-fused interleukin-7 provides long-lasting prophylaxis against lethal influenza virus infection." Journal of virology 90.5 (2016): 2273-2284.   https://doi.org/10.1128/jvi.02768-15
  20. Seo, Yong Bok, et al. "Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity." Journal of virology 88.16 (2014): 8998-9009.   https://doi.org/10.1128/JVI.00534-14
  21. Ahn, So-Shin, et al. "Nonlytic Fc-fused NT-I7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis." Vaccine 31.27 (2013): 2884-2890.   https://doi.org/10.1016/j.vaccine.2013.04.029
  22. Nam, Hyo Jung, et al. "Marked enhancement of antigen‐specific T‐cell responses by IL‐7‐fused nonlytic, but not lytic, Fc as a genetic adjuvant." European journal of immunology 40.2 (2010): 351-358.   https://doi.org/10.1002/eji.200939271
* Posters presented by Genexine, Inc.
CLOSE